Booming rare disease player Shire adding a trendy new R&D hub in Kendall Square for 1,000-plus
Shire CEO Flemming Ornskov has already made it clear that he intends to make the company a leading force in rare disease drug development and marketing. Now he’s moving to also make it one of the most visible players in the field.
Ornskov has inked a lease for the 343,000-square-foot building at 500 Kendall Street, right next to the 650 Kendall Street address it already owns. The plan is to turn Genzyme’s old facility into a rare disease innovation hub with more than 1,000 staffers. And it plans to move in cross-disciplinary teams involved in research, clinical development, medical affairs, business development and more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
